Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 49, Issue 12, 1999, Pages 992-996

  Marzo, Antonio ^a   Bo, Lorenzo Dal ^a   Mazzucchelli, Paolo ^a   Monti, Nunzia Ceppi ^a   Tettamanti, Rosella Alcotti ^a   Crivelli, Fabrizio ^a   Uhr, Mario Richard ^a   Ismaili, Shevquet ^a   Giusti, Andrea ^b  

^a Inst Pharmacokin/Analyt S SA   (Switzerland)

^b Menarini Ricerche SpA   (Italy)

Author keywords

Angiotensin converting enzyme inhibitor; CAS 81938 43 4; Zofenopril, pharmacodynamics, pharmacokinetics, plasma concentrations; Zofenoprilat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ZOFENOPRIL; ZOFENOPRILAT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; SYSTEMIC VASCULAR RESISTANCE;

EID: 0033376670     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300539     Document Type: Article

References (7)

1. Zofenopril calcium (MEN 8029), Investigator Brochure. Menarini Ricerche S.p.A., Data on Sponsor file (1996)
2. Foley, J., Brennan, J., Schindler, J. et al., The pharmacokinetics of SQ 26,333 measured by gas chromatography / mass spectrometry and radioimmunoassay, in healthy volunteers given single 15,30 and 60 mg doses of zofenopril. Menarini Ricerche S.p.A., Data on Sponsor file (1988)
3. Zanini, G. M., Swiss regulations for controlling clinical trials. Pharmacol. Res. 37, 321 (1998)
4. Marzo, A., Pharmacokinetic analysis, bioavailability and operating guidelines. J. Pharm. Pharmacol. 49, 1259 (1997)
5. Thind, G. S., Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics and pharmacodynamics. Cardiovasc. Drugs Ther. 4, 199 (1990)
6. Kelly, J. G., O'Malley, K., Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin. Pharmacokinet. 19, 177 (1990)
7. Marzo, A., Uhr, M. R., Giusti, A., Evaluation of the angiotensin converting enzyme inhibition activity of zofenopril following administration of three oral ascending doses to healthy volunteers. Menarini Ricerche S.p.A., Data on Sponsor file (1997)